Abstract

We attempt to discuss the effect of metformin combined with dapagliflozin on homocysteine, cystatin-c and beta-2 microglobulin levels in patients with type 2 diabetes mellitus. We selected 150 type 2 diabetes mellitus patients treated in our hospital from July 2018 to October 2021. According to random number table method, we divided them into observation group (metformin tablets combined with dapagliflozin tablets) and control group (metformin hydrochloride tablets), with 75 cases in each group. All were continuously treated for 24 w. After treatment, compared both groups on blood glucose level, islet function indexes levels before and after treatment, homocysteine, cystatin-c, beta-2 microglobulin and lipid metabolism indexes, and then recorded adverse reactions rate of both groups. After treatment, observation group possessed lower fasting blood glucose, 2 h postload blood glucose, hemoglobin A1c and body mass index levels than control group (p<0.05), and lower homocysteine, cystatin-c and beta-2 microglobulin levels than control group (p<0.05). Observation group possessed higher high-density lipoprotein cholesterol, homeostasis model assessment-beta cell function and low-density lipoprotein cholesterol levels than control group, but lower triglyceride, homeostasis model assessment-insulin resistance and total cholesterol levels than control group (p<0.05). The adverse reactions rate of observation group (13.33 %) had no remarkable difference with control group (9.33 %) (p>0.05). Metformin combined with dapagliflozin can effectively reduce homocysteine, cystatin-c and beta-2 microglobulin levels in type 2 diabetes mellitus patients with good safety.